News >

Genetic Testing, PARP Inhibitors Lead to Transformed Pancreatic Cancer Paradigm

Brittany Cote
Published: Friday, Feb 14, 2020

Eileen M. O'Reilly, MD, the associate director for Clinical Research in the David M. Rubenstein Center for Pancreatic Cancer Research and the Winthrop Rockefeller chair of Medical Oncology at Memorial Sloan Kettering Cancer Center

Eileen M. O’Reilly, MD

Conducting germline testing on patients with pancreatic cancer, and potentially treating them with PARP inhibitors in the maintenance setting, has become a novel approach in the paradigm, according to Eileen O’Reilly, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication